Replies to post #8637 on Provectus Biopharmaceuticals Inc (PVCT)

[bombaytonic]

Are you Billy Ackman? Haha, great post and I agree. It's perfect for an activist investor to step in and clean up the board and unlock the value.

[bombaytonic]

Is this essentially a declaration that we will be seeing some 13Ds coming out next week from you or some known associates?

[24seven]

"Net across all investments, next week should bare developments towards proper valuation. Hold onto your shares and ride the lightning north"
Lol...I'm going for it. I read through to page 28. I quit.
Assuming that all 19,945,132 Units are sold in the Rights Offering (which number is an estimated maximum amount of Units, calculated by using the number of shares of common stock and Listed Warrants outstanding as of December 30, 2016 and including in such amount the number of shares of common stock issuable upon conversion of the remaining outstanding shares of Series B Preferred Stock as of December 30, 2016), after deducting fees and expenses payable to the dealer-manager, and after deducting other expenses payable by us, we estimate the net proceeds of the Rights Offering will be approximately $ million. We intend to use approximately $15.6 million of the net proceeds from the exercise of Subscription Rights for clinical development, consisting of: approximately $9.3 million to expand the geographic scope necessary to complete patient accrual in our ongoing phase 3 clinical trial of PV-10 to treat locally advanced cutaneous melanoma; approximately $3.6 million to complete patient accrual in the phase 1b portion and begin the phase 2 portion of our phase 1b/2 combination study of PV-10 and Merck’s
KEYTRUDA in late stage melanoma; approximately $1.2 million to conduct our phase 1b/2 study of PV-10 in liver cancer (hepatocellular carcinoma); and approximately $1.5 million to conduct exploratory pre-clinical studies and phase 1 clinical studies to support current and future oncology indications. We intend to use any remaining net proceeds for working capital and general corporate purposes. See “Use of Proceeds.”
p.22
Page 28 & 29 Contain info about Culpepper and Dees
https://www.sec.gov/Archives/edgar/data/315545/000119312517013156/d274304ds1a.htm
GLTA

[bombaytonic]

When do we get to ride the lightning?